Back

SARS-CoV-2 post-vaccine surveillance studies in Australian children and adults with cancer: SerOzNET Quality of Life, Toxicity and Vaccine Beliefs Substudy Statistical Analysis Plan

Donoghue, M. W.; Body, A. L.; Wakefield, C.; Ahern, E. S.; Segelov, E.

2023-03-03 oncology
10.1101/2023.02.28.23286595 medRxiv
Show abstract

COVID-19 disease is associated with higher morbidity and mortality in cancer patients. SerOzNET is a prospective cohort study of adults and children with cancer undergoing routine SARS-CoV-2 vaccination in Australia. Peripheral blood was collected and processed at multiple points (one pre-vaccination and five or more post-vaccination) to address the primary aim of the study to assess the serological and immunological responses to vaccination. A secondary aim of the study was to "document patient response to vaccination using qualitative measures, including patient-reported outcomes, vaccine hesitancy survey and post-hoc toxicity recording" (body, et al.,2022). This statistical analysis plan describes the analysis of the data collected to address this aim. We will refer to this as the SerOzNET QoL Substudy. We have no conflicts of interest to disclose.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
BMJ Open
● 601 papers in training set
Top 0.2%
40.9%
Similar papers in this journal
2
PLOS ONE
● 5266 papers in training set
Top 23%
7.0%
Similar papers in this journal
3
Vaccines
○ 198 papers in training set
Top 0.7%
4.5%
Similar papers in this journal
50% of probability mass above
4
Vaccine
○ 203 papers in training set
Top 0.7%
4.2%
Similar papers in this journal
5
JAMA Network Open
● 130 papers in training set
Top 1%
3.3%
Similar papers in this journal
6
The Lancet Regional Health - Americas
○ 22 papers in training set
Top 0.2%
2.2%
7
eLife
● 5828 papers in training set
Top 44%
2.2%
8
The Lancet Infectious Diseases
○ 73 papers in training set
Top 0.6%
1.8%
9
Nature Communications
○ 5641 papers in training set
Top 44%
1.8%
10
Frontiers in Oncology
○ 103 papers in training set
Top 2%
1.8%
11
PeerJ
◐ 308 papers in training set
Top 6%
1.6%
12
Trials
○ 29 papers in training set
Top 0.6%
1.5%
13
Journal for ImmunoTherapy of Cancer
● 75 papers in training set
Top 1%
1.5%
14
Human Vaccines & Immunotherapeutics
○ 25 papers in training set
Top 0.3%
1.2%
15
Frontiers in Immunology
○ 638 papers in training set
Top 7%
1.2%
16
Cancer Medicine
○ 26 papers in training set
Top 0.8%
1.1%
17
PLOS Global Public Health
● 344 papers in training set
Top 8%
0.9%
18
Cancer Immunology, Immunotherapy
○ 12 papers in training set
Top 0.2%
0.9%
19
Vaccine: X
○ 22 papers in training set
Top 0.5%
0.9%
20
Journal of Psychosomatic Research
○ 13 papers in training set
Top 0.3%
0.9%
21
eClinicalMedicine
○ 77 papers in training set
Top 2%
0.9%
22
Life
○ 29 papers in training set
Top 1%
0.6%
23
Database
◐ 61 papers in training set
Top 1%
0.6%
24
The Lancet
○ 16 papers in training set
Top 0.3%
0.6%
25
JCO Clinical Cancer Informatics
● 22 papers in training set
Top 0.8%
0.6%
26
The Lancet Respiratory Medicine
○ 19 papers in training set
Top 0.3%
0.6%
27
Drug Safety
○ 10 papers in training set
Top 0.3%
0.6%
28
Scientific Reports
○ 3612 papers in training set
Top 75%
0.6%
29
Med
○ 39 papers in training set
Top 0.9%
0.6%
30
Brain, Behavior, & Immunity - Health
○ 28 papers in training set
Top 0.6%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.